Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations.
Saved in:
| Title: | Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. |
|---|---|
| Authors: | DeLeon TT; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Almquist DR; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Kipp BR; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Langlais BT; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Mangold A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Winters JL; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Kosiorek HE; Department of Biostatistics, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Joseph RW; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Dronca RS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Block MS; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., McWilliams RR; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Kottschade LA; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Rumilla KM; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Voss JS; Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Seetharam M; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America., Sekulic A; Department of Dermatology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America.; Mayo Clinic Cancer Center, Phoenix, Arizona, United States of America., Markovic SN; Department of Hematology & Oncology, Mayo Clinic Rochester, Rochester, Minnesota, United States of America., Bryce AH; Department of Hematology & Oncology, Mayo Clinic Arizona, Scottsdale, Arizona, United States of America. |
| Source: | PloS one [PLoS One] 2020 Mar 20; Vol. 15 (3), pp. e0230306. Date of Electronic Publication: 2020 Mar 20 (Print Publication: 2020). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
